(Reuters) – Europe’s drug regulator said on Tuesday it had started a real-time review of the COVID-19 vaccine being developed by French drugmaker Sanofi and Britain’s GlaxoSmithKline.
The decision to start the “rolling review” of the vaccine, called Vidprevtyn, was based on early results from lab studies and early stage clinical studies in adults, the European Medicines Agency said, without giving further details.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Sriraj Kalluvila)
